Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

How Sharesies is providing ‘patient’ capital for listeds
Finance

How Sharesies is providing ‘patient’ capital for listeds

The online platform is being tapped for bookbuilds and dividend reinvestment plans.

NZX rallies 0.87% as tariff uncertainty eases
Markets Market Close

NZX rallies 0.87% as tariff uncertainty eases

Skellerup bounced 4.11% as investors digested easing tariffs. 

Gregor Thompson 13 May 2025
Flick not profitable before $70m sale to Meridian
Markets

Flick not profitable before $70m sale to Meridian

After eight years of trying in electricity retailing, Z throws in the towel.

Ian Llewellyn 13 May 2025
Vista to take 25 Picturehouse Cinema sites to the cloud in 2025
Markets

Vista to take 25 Picturehouse Cinema sites to the cloud in 2025

The listed cinema software firm has its AGM on May 21.